vidarabine has been researched along with entinostat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Acharya, MR; Figg, WD | 1 |
| Chen, B; Fang, Q; He, Z; Li, P; Ma, D; Ren, M; Wang, J; Zhe, N; Zhong, Q; Zhou, Z | 1 |
3 other study(ies) available for vidarabine and entinostat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Cycle Proteins; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Pyridines; Reactive Oxygen Species; Vidarabine | 2004 |
Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Heme Oxygenase-1; Histone Deacetylase 1; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Nude; Middle Aged; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Random Allocation; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine; Xenograft Model Antitumor Assays | 2019 |